Covered recipient · General Payments record
JOHN PULLMAN
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$2,969.30
76 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,536.20 | 72 |
| Travel and Lodging | $870.60 | 3 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $562.50 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Boehringer Ingelheim International GmbH | $1,360.60 | 11 |
| Melinta Therapeutics, LLC | $562.50 | 1 |
| Novo Nordisk Inc | $225.22 | 16 |
| AstraZeneca Pharmaceuticals LP | $189.86 | 8 |
| Lilly USA, LLC | $168.25 | 13 |
| Amgen Inc. | $157.62 | 8 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $81.35 | 6 |
| ABBVIE INC. | $70.15 | 3 |
| GlaxoSmithKline, LLC. | $43.00 | 3 |
| Bayer Healthcare Pharmaceuticals Inc. | $31.50 | 2 |
| Novartis Pharmaceuticals Corporation | $27.57 | 2 |
| Xeris Pharmaceuticals, Inc. | $24.58 | 1 |
| Exact Sciences Corporation | $15.06 | 1 |
| PFIZER INC. | $12.04 | 1 |
Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JOHN PULLMAN
NPI 1518998426 · CMS profile ID 159679
Allopathic & Osteopathic Physicians / Internal Medicine
BUTTE, MT
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1518998426?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JOHN PULLMAN, NPI 1518998426, CMS profile ID 159679. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518998426?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). JOHN PULLMAN, NPI 1518998426, CMS profile ID 159679. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518998426?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- JOHN PULLMAN, NPI 1518998426, CMS profile ID 159679, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1518998426?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
76 matching records · $2,969.30 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–76 of 76.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | $13.42 | 04/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001488995 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $13.86 | 04/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996982041 | CMS |
| Lilly USA, LLC | $11.74 | 04/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031630563 | CMS |
| Amgen Inc. | $35.54 | 04/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1019972487 | CMS |
| Novo Nordisk Inc | $9.09 | 04/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001720981 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.29 | 03/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015904581 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.96 | 03/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014909617 | CMS |
| Novo Nordisk Inc | $6.50 | 03/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001720961 | CMS |
| Novo Nordisk Inc | $14.45 | 03/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001721019 | CMS |
| Amgen Inc. | $22.11 | 03/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1019972485 | CMS |
| Lilly USA, LLC | $11.93 | 03/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031711573 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.28 | 02/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014912041 | CMS |
| GlaxoSmithKline, LLC. | $14.86 | 02/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001488298 | CMS |
| Amgen Inc. | $6.83 | 02/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020605675 | CMS |
| Xeris Pharmaceuticals, Inc. | $24.58 | 02/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056470105 | CMS |
| Lilly USA, LLC | $10.21 | 02/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031592911 | CMS |
| Novo Nordisk Inc | $10.53 | 02/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001720991 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $0.79 | 02/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996982045 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $29.42 | 02/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996982049 | CMS |
| Exact Sciences Corporation | $15.06 | 01/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026541671 | CMS |
| Novo Nordisk Inc | $22.53 | 01/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001745847 | CMS |
| ABBVIE INC. | $31.12 | 01/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998170977 | CMS |
| Amgen Inc. | $18.33 | 01/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1019972489 | CMS |
| AstraZeneca Pharmaceuticals LP | $86.15 | 01/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1011435831 | CMS |
| Lilly USA, LLC | $10.75 | 01/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031577537 | CMS |
| Lilly USA, LLC | $14.00 | 01/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031711569 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $500,898.60 | 155 |
| PY2024 | Recipient | $3,263.84 | 23 |
| PY2024 | Principal investigator | $408,443.37 | 185 |
| PY2023 | Recipient | $690.05 | 1 |
| PY2023 | Principal investigator | $955,108.44 | 87 |
| PY2022 | Principal investigator | $601,386.60 | 342 |
| PY2021 | Principal investigator | $2,005,376.91 | 273 |
| PY2020 | Recipient | $12,120.19 | 2 |
| PY2020 | Principal investigator | $1,003,285.37 | 105 |
| PY2019 | Principal investigator | $469,488.06 | 173 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
155 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $5,520.00 | 12/31/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism | No dispute reported | 06/30/2026 | 1202534367 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $4,754.00 | 12/19/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211624542 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 12/17/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673322 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.96 | 12/17/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673324 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,629.70 | 12/15/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220797441 |
| Principal investigator 1 | ABBVIE INC. | $1,146.60 | 12/05/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202529310 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,902.97 | 12/04/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184269405 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673304 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673306 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673308 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673310 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673312 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673314 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $10,154.00 | 11/20/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211624538 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $19,320.00 | 11/14/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211624534 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19,107.00 | 11/13/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220797439 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 11/06/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220797437 |
| Principal investigator 1 | ABBVIE INC. | $14,320.80 | 11/05/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202522435 |
| Principal investigator 1 | Novo Nordisk AS | $500.00 | 11/05/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP, PLLC | NN9535-4801 | No dispute reported | 06/30/2026 | 1213748161 |
| Principal investigator 1 | Novo Nordisk AS | $1,000.00 | 11/05/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP, PLLC | NN9535-4801 | No dispute reported | 06/30/2026 | 1213761560 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673292 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673294 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673296 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673298 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673300 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673302 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 10/27/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673316 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 10/27/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673318 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.32 | 10/27/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673320 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $24,272.65 | 10/27/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP, PLLC | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190306851 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $14,798.00 | 10/16/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211624531 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,600.16 | 10/16/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184250821 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,926.01 | 10/09/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184249070 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673280 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673282 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673284 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673286 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673288 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673290 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 09/24/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673276 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.44 | 09/24/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673278 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $840.60 | 09/18/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220797435 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,268.64 | 09/18/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184240628 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.79 | 09/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673228 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673240 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673242 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673244 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673246 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673248 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673264 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $81.62 | 08/26/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673270 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 08/26/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673272 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $18.75 | 08/26/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673274 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,838.67 | 08/26/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184230659 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,500.66 | 08/21/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184229789 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14,510.70 | 08/06/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220797433 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673230 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673232 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673234 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673236 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673238 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673262 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 07/28/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673266 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.74 | 07/28/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673268 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,316.06 | 07/22/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184217879 |
| Principal investigator 1 | Novo Nordisk AS | $5,036.40 | 07/21/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP, PLLC | NN9535-4801 | No dispute reported | 06/30/2026 | 1213757056 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,184.60 | 07/04/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184212949 |
| Principal investigator 1 | ABBVIE INC. | $3,923.40 | 07/02/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202494395 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673250 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673252 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673254 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673256 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673258 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673260 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,372.20 | 06/26/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220797431 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 06/24/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673222 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $18.75 | 06/24/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673224 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.70 | 06/24/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673226 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $434.27 | 06/24/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184210718 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,128.38 | 06/12/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184206467 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,930.40 | 06/11/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220797429 |
| Principal investigator 1 | ABBVIE INC. | $14,859.00 | 06/03/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202489729 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673198 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673200 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673202 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673204 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673206 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673208 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,000.00 | 05/28/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184198973 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,041.00 | 05/28/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184198975 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,422.00 | 05/28/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184198977 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,487.28 | 05/28/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184198979 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26,938.60 | 05/28/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184198981 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 05/27/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673218 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.96 | 05/27/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673220 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75,347.86 | 05/23/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184198431 |
| Principal investigator 1 | ABBVIE INC. | $3,439.80 | 05/07/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202483409 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 05/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673182 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $49.88 | 05/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673184 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 05/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673186 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673188 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673190 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673192 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673194 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673196 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,382.60 | 05/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220797427 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.30 | 04/23/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673210 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $279.72 | 04/23/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673212 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 04/23/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673214 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $38.64 | 04/23/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673216 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673170 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673172 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673174 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673176 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673178 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 04/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673180 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 03/25/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673166 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $11,673.90 | 03/25/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220797425 |
| Principal investigator 1 | Eli Lilly and Company | $14,058.00 | 03/11/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH, INC | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187887666 |
| Principal investigator 1 | ABBVIE INC. | $3,568.50 | 03/07/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202459317 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673146 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673148 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673150 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673152 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673154 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 03/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673156 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 02/25/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673162 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.48 | 02/25/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673164 |
| Principal investigator 1 | Novo Nordisk AS | $4,095.00 | 02/21/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP, PLLC | NN9535-4801 | No dispute reported | 06/30/2026 | 1213823931 |
| Principal investigator 1 | Eli Lilly and Company | $60.20 | 02/20/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH, INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187887668 |
| Principal investigator 1 | Eli Lilly and Company | $1,254.36 | 02/14/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH, INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187886896 |
| Principal investigator 1 | ABBVIE INC. | $5,514.60 | 02/06/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202449209 |
| Principal investigator 1 | PFIZER INC. | $10,065.00 | 02/06/2025 | Non-covered Recipient Entity Mercury Street Medical Group PLLC | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228837907 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673134 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673136 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673138 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673140 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673142 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 02/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673144 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 01/27/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673158 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.22 | 01/27/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673160 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,208.80 | 01/27/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220797423 |
| Principal investigator 1 | Eli Lilly and Company | $219.60 | 01/27/2025 | Non-covered Recipient Entity CLINVEST RESEARCH LLC | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187879281 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $6,672.00 | 01/24/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL | A Phase 3 Randomized Open label Study to Assess the Immunogenicity and Safety of IVX A12 when Co-administered with a licensed influenza vaccine | No dispute reported | 06/30/2026 | 1185550311 |
| Principal investigator 1 | Eli Lilly and Company | $49,265.00 | 01/21/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH, INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187886428 |
| Principal investigator 1 | Eli Lilly and Company | $23,208.00 | 01/21/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH, INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187889254 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,286.20 | 01/17/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220797419 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $225.00 | 01/06/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220797421 |
| Principal investigator 1 | ABBVIE INC. | $2,828.80 | 01/02/2025 | Non-covered Recipient Entity MERCURY STREET MEDICAL GROUP PLLC | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202435703 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673124 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673126 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673128 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673130 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673132 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 01/01/2025 | Non-covered Recipient Entity Mercury Street Medical | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220673168 |